Spotlight Medical, a Paris-based precision medicine company aiming to solve “the critical issue of inadequate cancer treatments”, has successfully secured €6.2 million in seed funding for AI-driven prognosis tests designed to help improve cancer treatment.
Spotlight Medical shared news of the funding on LinkedIn, highlighting how it would help to bring these prognosis tests to clinics with the aim of “significantly improving cancer treatment strategies”.
Benjamin Belot, a partner at Kurma Partners, one of the venture capital groups leading on the funding round, spoke of being “impressed” by the team’s quality and their “unique technology”, which he called “unlike anything in precision oncology”.
Christian Lautner, a partner at Heal Capital, who also led the funding round, shared the belief that Spotlight Medical’s AI-empowered precision oncology platform could “have a lasting impact on patients’ lives”.
Spotlight Medical was launched at the end of June 2024 with the mission to “unlock personalised care for every patient”, as a spin-off from Institut Curie, an institute which brings together 3,000 researchers, clinicians and technicians in a multidisciplinary approach to cancer.
In other funding news, San Francisco-based Better Health has announced the securing of $14 million in funding for its solution providing support for those with chronic illness. The new funding will be used to offer “a more comprehensive solution” for payers and providers, and to support expansion into “new categories”, whilst also allowing for the exploration of the ways in which AI might enhance the patient, payer and provider experience.
- 1
- 2
